Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.

Breast (Edinburgh, Scotland) - 1 Aug 2024

Wang Ru, Wang Bin, Zhang Huimin, Liao Xiaoqin, Shi Bohui, Zhou Yuhui, Zhou Can, Yan Yu, Zhang Wei, Wang Ke, Ge Guanqun, Ren Yu, Tang Xiaojiang, Gan Baoyu, He Jianjun, Niu Ligang

Abstract excerpt

BACKGROUND: We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to primary systemic therapy (PST) in breast cancer and evaluated the predictive value of ctDNA to further identify patients with residual disease. METHODS: We prospectively enrolled 208 plasma samples collected at three time points (before PST, after 2 cycles of treatment, before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm, Residual

Share to Neoplasm Staging

Share to Predictive Value of Tests

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 38685149
DOI: 10.1016/j.breast.2024.103738
PMCID: PMC11067540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.PMID 38685149Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read ↗

Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast CancerSemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read ↗

Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.Semantic proximity Read ↗

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.